Virtual reality vs active intervention (short term)
Number of adverse events · rehabilitation in Parkinson's disease
1 finding from 1 review
- no estimate extracted4 studies · 115 participantsLow
Findings
What do systematic reviews say?
9 questions · 9 findings · 6 reviews · Movement Disorders
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 22.2%Low 2 · 22.2%Moderate 4 · 44.4%High 1 · 11.1%
Zonisamide vs placebo
Adverse events Number of adverse events · patients with essential tremor
It is very uncertain whether zonisamide changes adverse events Number of adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RD 0.6 [0.28, 0.92]1 study · 20 participantsVery low
Intervention not reported
Adverse events Number of adverse events · patients with essential tremor
It is very uncertain whether the intervention changes adverse events Number of adverse events (very low certainty).
1 finding from 1 review
- RD 0.181 study · 22 participantsVery low
Dopamine agonist vs placebo
Withdrawals due to adverse events · patients with restless legs syndrome according to IRLSSG, 18 years or older
Summary of findings: dopamine agonists leads to higher number of dropouts due to adverse events compared with placebo (high certainty).
1 finding from 1 review
- Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes onlyOR 1.82 [1.35, 2.45]34 studies · 7054 participantsHigh
Summary of findings: levodopa vs other dopamine agonists
Adverse effects (drop‐outs due to adverse effects4) · patients with restless legs syndrome
Summary of findings: levodopa probably leads to lower number of drop outs due to adverse events compared with other dopamine agonists (moderate certainty).
1 finding from 1 review
- OR 0.593 studies · 504 participantsModerate
Dopamine agonist vs levodopa
Adverse effects (drop‐outs due to adverse effects4) · patients with restless legs syndrome
Summary of findings: dopamine agonists probably leads to higher number of drop outs due to adverse events compared with levodopa (moderate certainty).
1 finding from 1 review
- Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes onlyOR 1.73 studies · 504 participantsModerate
Dopamine agonist vs levodopa
Number of participants reporting an adverse event · patients with restless legs syndrome
Summary of findings: dopamine agonists showed no clear difference in number of patients experiencing adverse events compared with levodopa (moderate certainty).
1 finding from 1 review
- Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes onlyOR 2.87 [0.43, 19]3 studies · 461 participantsModerate
Treadmill training vs no treadmill training or active control intervention or gait training
acceptability and safety of treadmill training ‐ Active control group (co‐interventions were similar in both groups) Number of adverse events and drop‐outs · people with Parkinson's disease
1 finding from 1 review
- no estimate extracted15 studies · 531 participantsModerate
Treadmill training vs no treadmill training or active control intervention or gait training
acceptability and safety of treadmill training ‐ No intervention control group (co‐interventions were not similar in both groups) Number of adverse events and drop‐outs · people with Parkinson's disease
1 finding from 1 review
- no estimate extracted3 studies · 102 participantsLow